Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · IEX Real-Time Price · USD
84.85
+2.71 (3.30%)
At close: Jul 19, 2024, 4:00 PM
86.44
+1.59 (1.87%)
Pre-market: Jul 22, 2024, 7:30 AM EDT
Axsome Therapeutics Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for Axsome Therapeutics stock have an average target of 125.25, with a low estimate of 95 and a high estimate of 190. The average target predicts an increase of 47.61% from the current stock price of 84.85.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for AXSM stock from 13 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 6 | 6 | 6 | 7 |
| Buy | 3 | 4 | 5 | 5 | 5 | 5 |
| Hold | 2 | 2 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 12 | 12 | 12 | 12 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Initiates $130 | Strong Buy | Initiates | $130 | +53.21% | Jul 22, 2024 |
| B of A Securities | B of A Securities | Hold Maintains $97 → $95 | Hold | Maintains | $97 → $95 | +11.96% | Jul 18, 2024 |
| Mizuho | Mizuho | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Jun 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $190 | Strong Buy | Reiterates | $190 | +123.92% | Jun 6, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $127 → $130 | Buy | Maintains | $127 → $130 | +53.21% | Jun 5, 2024 |
Financial Forecast
Revenue This Year
383.76M
from 270.60M
Increased by 41.82%
Revenue Next Year
684.92M
from 383.76M
Increased by 78.48%
EPS This Year
-4.93
from -5.27
EPS Next Year
-0.48
from -4.93
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 464.9M | 919.1M | 1.8B | 2.3B | 2.8B |
| Avg | 383.8M | 684.9M | 1.2B | 1.6B | 2.1B |
| Low | 340.2M | 458.4M | 856.8M | 1.2B | 1.6B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 71.8% | 139.5% | 155.8% | 95.6% | 73.7% |
| Avg | 41.8% | 78.5% | 72.6% | 36.6% | 27.6% |
| Low | 25.7% | 19.4% | 25.1% | 5.6% | -1.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -3.80 | 3.57 | 14.49 | 12.79 | 18.09 |
| Avg | -4.93 | -0.48 | 6.38 | 8.58 | 12.97 |
| Low | -6.10 | -3.90 | -0.91 | 2.68 | 8.57 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 100.3% | 110.9% |
| Avg | - | - | - | 34.4% | 51.2% |
| Low | - | - | - | -58.1% | -0.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.